{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:23Z","timestamp":1794047543075,"version":"4.8.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1038\/s41380-023-02266-x","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T11:04:40Z","timestamp":1697022280000},"page":"3648-3660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-0853","authenticated-orcid":false,"given":"Michele","family":"Fornaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Caiazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Solini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Prisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Billeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Vannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Caiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialaura","family":"Lussignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Pigato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Sambataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"de Bartolomeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"2266_CR1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jobcr.2019.06.009","volume":"9","author":"AA Mohandoss","year":"2019","unstructured":"Mohandoss AA, Thavarajah R. Salivary flow alteration in patients undergoing treatment for schizophrenia: disease-drug-target gene\/protein association study for side-effects. J Oral Biol Craniofac Res. 2019;9:286\u201393.","journal-title":"J Oral Biol Craniofac Res"},{"key":"2266_CR2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","journal-title":"Lancet"},{"key":"2266_CR3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/YIC.0000000000000371","volume":"36","author":"JM Kane","year":"2021","unstructured":"Kane JM, Durgam S, Satlin A, Vanover KE, Chen R, Davis R, et al. Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. Int Clin Psychopharmacol. 2021;36:244\u201350.","journal-title":"Int Clin Psychopharmacol"},{"key":"2266_CR4","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264\u2013e278.","journal-title":"J Clin Psychiatry"},{"key":"2266_CR5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/wps.20579","volume":"17","author":"M Carbon","year":"2018","unstructured":"Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17:330\u201340.","journal-title":"World Psychiatry"},{"key":"2266_CR6","volume":"11","author":"E Wagner","year":"2021","unstructured":"Wagner E, Siafis S, Fernando P, Falkai P, Honer WG, R\u00f6h A, et al. Efficacy and safety of clozapine in psychotic disorders\u2014a systematic quantitative meta-review. Transl Psychiatry. 2021;11:487.","journal-title":"Transl Psychiatry"},{"key":"2266_CR7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3371\/1935-1232.10.3.163","volume":"10","author":"L Citrome","year":"2016","unstructured":"Citrome L, McEvoy JP, Saklad SR. Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses. 2016;10:163\u201377.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"2266_CR8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1192\/bja.2019.58","volume":"26","author":"S Gupta","year":"2020","unstructured":"Gupta S, Khastgir U, Croft M, Roshny S. Management of clozapine-induced sialorrhoea. BJPsych Adv. 2020;26:106\u20138.","journal-title":"BJPsych Adv"},{"key":"2266_CR9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40263-019-00612-8","volume":"33","author":"SY Chen","year":"2019","unstructured":"Chen SY, Ravindran G, Zhang Q, Kisely S, Siskind D. Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. CNS Drugs. 2019;33:225\u201338.","journal-title":"CNS Drugs"},{"key":"2266_CR10","doi-asserted-by":"crossref","unstructured":"Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, et al. Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev. 2008; Cd005579.","DOI":"10.1002\/14651858.CD005579.pub2"},{"key":"2266_CR11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12:103\u201311.","journal-title":"Intern Emerg Med"},{"key":"2266_CR12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/ebmental-2019-300104","volume":"22","author":"D Mavridis","year":"2019","unstructured":"Mavridis D. Network meta-analysis in a nutshell. Evid Based Ment Health. 2019;22:100\u20131.","journal-title":"Evid Based Ment Health"},{"key":"2266_CR13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00004714-200006000-00004","volume":"20","author":"KR Chengappa","year":"2000","unstructured":"Chengappa KR, Pollock BG, Parepally H, Levine J, Kirshner MA, Brar JS, et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol. 2000;20:311\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"2266_CR14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/02537176211025789","volume":"45","author":"A Halder","year":"2021","unstructured":"Halder A, Ravindran NP, Nagda P, Harshe D, Harshe G. Review of psychotropic agents associated with Sialorrhoea, except Clozapine. Indian J Psychol Med. 2021;45:14\u201318.","journal-title":"Indian J Psychol Med"},{"key":"2266_CR15","doi-asserted-by":"publisher","unstructured":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71. For more information, visit: http:\/\/www.prisma-statement.org\/. 2021, Accessed Date 2021.","DOI":"10.1136\/bmj.n71"},{"key":"2266_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-016-1678-5","volume":"17","author":"I Qurashi","year":"2016","unstructured":"Qurashi I, Chu S, Husain N, Drake RJ, Chaudhry I, Deakin J. Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): study protocol for a randomised controlled feasibility study. Trials. 2016;17:1\u20139.","journal-title":"Trials"},{"key":"2266_CR17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00213-009-1689-y","volume":"207","author":"S Steinlechner","year":"2010","unstructured":"Steinlechner S, Klein C, Moser A, Lencer R, Hagenah J. Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea. Psychopharmacology. 2010;207:593\u20137.","journal-title":"Psychopharmacology"},{"key":"2266_CR18","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"2266_CR19","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1002\/cl2.1080","volume":"16","author":"T Papakonstantinou","year":"2020","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins JP, Egger M, Salanti G. Cinema: software for semiautomated assessment of the confidence in the results of network meta\u2010analysis. Campbell Syst Rev. 2020;16:e1080.","journal-title":"Campbell Syst Rev"},{"key":"2266_CR20","doi-asserted-by":"crossref","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, et al. netmeta: An R Package for network meta-analysis using frequentist methods. J Stat Softw. 2023;106:1\u201340.","DOI":"10.18637\/jss.v106.i02"},{"key":"2266_CR21","unstructured":"Team R. RStudio: Integrated development for R. PBC: Boston, MA, 2020."},{"key":"2266_CR22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"J Higgins","year":"2012","unstructured":"Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I. Consistency and inconsistency in network meta\u2010analysis: concepts and models for multi\u2010arm studies. Res Synth Methods. 2012;3:98\u2013110.","journal-title":"Res Synth Methods"},{"key":"2266_CR23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","volume":"42","author":"AA Veroniki","year":"2013","unstructured":"Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42:332\u201345.","journal-title":"Int J Epidemiol"},{"key":"2266_CR24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163\u201371.","journal-title":"J Clin Epidemiol"},{"key":"2266_CR25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani A, Salanti G. Using network meta\u2010analysis to evaluate the existence of small\u2010study effects in a network of interventions. Res Synth Methods. 2012;3:161\u201376.","journal-title":"Res Synth Methods"},{"key":"2266_CR26","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.4088\/JCP.08m04495","volume":"70","author":"S Sockalingam","year":"2009","unstructured":"Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2009;70:1114\u20139.","journal-title":"J Clin Psychiatry"},{"key":"2266_CR27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JCP.0000000000000493","volume":"36","author":"A Kreinin","year":"2016","unstructured":"Kreinin A, Miodownik C, Mirkin V, Gaiduk Y, Yankovsky Y, Bersudsky Y, et al. Double-blind, randomized, placebo-controlled trial of metoclopramide for hypersalivation associated with clozapine. J Clin Psychopharmacol. 2016;36:200\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"2266_CR28","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1007\/s00213-020-05627-4","volume":"237","author":"O Mubaslat","year":"2020","unstructured":"Mubaslat O, Lambert T. The effect of sublingual atropine sulfate on clozapine-induced hypersalivation: a multicentre, randomised placebo-controlled trial. Psychopharmacol (Berl). 2020;237:2905\u201315.","journal-title":"Psychopharmacol (Berl)"},{"key":"2266_CR29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/YIC.0000000000000251","volume":"34","author":"A Segev","year":"2019","unstructured":"Segev A, Evans A, Hodsoll J, Whiskey E, Sheriff RS, Shergill S, et al. Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial. Int Clin Psychopharmacol. 2019;34:101\u20137.","journal-title":"Int Clin Psychopharmacol"},{"key":"2266_CR30","first-page":"34","volume":"03","author":"Z Li","year":"1993","unstructured":"Li Z, Song Z, Cheng P, Li C, Xiang X, Shi H. A double-blinded controlled trial on the use of astemizole in clozapine-induced sialorrhoea. Chin J Clin Psychiatry. 1993;03:34\u201335.","journal-title":"Chin J Clin Psychiatry"},{"key":"2266_CR31","first-page":"38","volume":"11","author":"X Lu","year":"1998","unstructured":"Lu X, Xue S, Yang M. The use of diphehydramine in clozapine-induced sialorrhoea. Sichuan J Ment Health. 1998;11:38\u201340.","journal-title":"Sichuan J Ment Health"},{"key":"2266_CR32","first-page":"252","volume":"27","author":"L Lu","year":"1994","unstructured":"Lu L, Liu G, Zhao J, Liu A, Liu S, Liu L, et al. A double blinded placebo-controlled trial on the use of chlorpheniramine in clozapine-induced sialorrhoea. Chin J Neurol. 1994;27:252\u20133.","journal-title":"Chin J Neurol"},{"key":"2266_CR33","first-page":"4","volume":"1","author":"H Yao","year":"1994","unstructured":"Yao H, Qu H, Li G. A double-blind controlled study of propantheline and astemizole in the treatment of salivation side effects of clozapine. Chin J Clin Psychiatry. 1994;1:4.","journal-title":"Chin J Clin Psychiatry"},{"key":"2266_CR34","first-page":"33","volume":"8","author":"Z Fan","year":"1996","unstructured":"Fan Z, Zheng C, Li S. placebo-controlled trial on the use of propantheline in clozapine-induced sialorrhoea. Strait Pharm J. 1996;8:33\u201334.","journal-title":"Strait Pharm J"},{"key":"2266_CR35","first-page":"12","volume":"8","author":"S Yang","year":"1996","unstructured":"Yang S, Xu S, Yuhua Y. Double-blind control of cyproheptadine and placebo in the treatment of side effects of clozapine-induced salivation. J Chin People\u2019s Health. 1996;8:12\u201313.","journal-title":"J Chin People\u2019s Health"},{"key":"2266_CR36","first-page":"138","volume":"31","author":"G Gong","year":"1998","unstructured":"Gong G, Yuan L, Qin D, Li H, Zhao L, Yang X, et al. A double-blind controlled study of diphenhydramine, propantheline, astemizole and placebo in the treatment of clozapine-induced sialorrhea. Chin J Psychiatry. 1998;31:138.","journal-title":"Chin J Psychiatry"},{"key":"2266_CR37","first-page":"205","volume":"16","author":"H Xu","year":"1997","unstructured":"Xu H, Dong A, Zhang T, Shu W. Different doses of diphenhydramine in the treatment of clozapine-induced salivation. N. Drugs Clin Rem. 1997;16:205\u20137.","journal-title":"N. Drugs Clin Rem"},{"key":"2266_CR38","first-page":"451","volume":"22","author":"H Yang","year":"1999","unstructured":"Yang H, Huang S, Feng C, Chen J. Study on the treatment of salivation induced by clozapine. J Binzhou Med Univ. 1999;22:451.","journal-title":"J Binzhou Med Univ"},{"key":"2266_CR39","first-page":"141","volume":"7","author":"J Tao","year":"2007","unstructured":"Tao J, Yin X, Liu J. A randomized controlled study of sulpiride in the treatment of clozapine-induced salivation. J Neurosci Ment Health. 2007;7:141\u20133.","journal-title":"J Neurosci Ment Health"},{"key":"2266_CR40","first-page":"15","volume":"17","author":"Z Zhang","year":"1999","unstructured":"Zhang Z, Sun T. Comparative observation of the effect of diphenhydramine and doxepin in treatment of salivation caused by clozapine. J Huaihai Med. 1999;17:15\u201316.","journal-title":"J Huaihai Med"},{"key":"2266_CR41","unstructured":"Zhou Y. Clinical observation of chlorpheniramine in the treatment of salivation caused by clozapine. Linchuang jingshen yixue zazhi. J Clin Psychiatry. 2009;19:132\u20133."},{"key":"2266_CR42","unstructured":"Zhou H, Zhang Q. A double-blind controlled study of doxepin and propantheline in the treatment of clozapine-induced hypersalivation. Linchuang jingshen yixue zazhi. J Clin Psychiatry. 1996;6:300."},{"key":"2266_CR43","first-page":"731","volume":"18","author":"M Yang","year":"1997","unstructured":"Yang M, Xue S, Wen Q. A double-blind controlled study of diphenhydramine and propantheline in the treatment of salivation side effects of clozapine. Guangdong Med J. 1997;18:731.","journal-title":"Guangdong Med J"},{"key":"2266_CR44","unstructured":"Wang S, Song W, Gu W. Comparison of doxepin and astemizole in the treatment of clozapine-induced salivation. Shanghai Arch Psychiatry. 1998;10:176\u20137."},{"key":"2266_CR45","first-page":"17","volume":"9","author":"Y Song","year":"1996","unstructured":"Song Y, Feng X, Lv Y, Zhang S. A comparative study of doxepin and propantheline in the treatment of clozapine-induced sialorrhea. Shandong Arch Psychiatry. 1996;9:17\u20139.","journal-title":"Shandong Arch Psychiatry"},{"key":"2266_CR46","first-page":"316","volume":"25","author":"H Lin","year":"1999","unstructured":"Lin H. Double-blind comparison of propantheline and placebo in the treatment of salivation side effects of clozapine. Chin J Neuropsychiatr Dis. 1999;25:316\u20137.","journal-title":"Chin J Neuropsychiatr Dis"},{"key":"2266_CR47","first-page":"176","volume":"19","author":"D Li","year":"2003","unstructured":"Li D, Xu M, Duan X. A comparative observation of cyproheptadine and propantheline in the treatment of clozapine-induced salivation. Occup Health. 2003;19:176\u20137.","journal-title":"Occup Health"},{"key":"2266_CR48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/JCP.0000000000000657","volume":"37","author":"WH Man","year":"2017","unstructured":"Man WH, Colen-de Koning JC, Schulte PF, Cahn W, van Haelst IM, Doodeman HJ, et al. The effect of glycopyrrolate on nocturnal sialorrhea in patients using clozapine: a randomized, crossover, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2017;37:155\u201361.","journal-title":"J Clin Psychopharmacol"},{"key":"2266_CR49","first-page":"111","volume":"88","author":"Z Li","year":"2015","unstructured":"Li Z, Wang Q. A controlled study of amisulpride in the treatment of clozapine-induced sialorrhea. World\u2019s Latest Med Inf Dig. 2015;88:111.","journal-title":"World\u2019s Latest Med Inf Dig"},{"key":"2266_CR50","first-page":"115","volume":"54","author":"C Li","year":"2011","unstructured":"Li C. Observation on the efficacy of promethazine in the treatment of adverse reactions of clozapine salivation. Chin Manip Rehabilit Med. 2011;54:115.","journal-title":"Chin Manip Rehabilit Med"},{"key":"2266_CR51","first-page":"225","volume":"9","author":"J Qin","year":"1999","unstructured":"Qin J, Cui C, Ge F. A comparison of treatments for clozapine-induced sialorrhea. Chin J Clin Psychiatry. 1999;9:225\u20136.","journal-title":"Chin J Clin Psychiatry"},{"key":"2266_CR52","first-page":"288","volume":"10","author":"G Yu","year":"2000","unstructured":"Yu G, Ding G, Liang S. Treatment of clozapine-induced sialorrhea. Chin J Clin Psychiatry. 2000;10:288.","journal-title":"Chin J Clin Psychiatry"},{"key":"2266_CR53","first-page":"2135","volume":"14","author":"J Cheng","year":"2005","unstructured":"Cheng J, Jiang S. A study on the use of benzhexol in the treatment of clozapine-induced sialorrhea. Mod J Integr Tradit Chin West Med. 2005;14:2135\u20136.","journal-title":"Mod J Integr Tradit Chin West Med"},{"key":"2266_CR54","first-page":"111","volume":"26","author":"J Wang","year":"2000","unstructured":"Wang J, Ning Y, Wang W, Yu J. A double-blind controlled study of cyproheptadine and benzhexol in the treatment of clozapine-induced sialorrhea. Chin J Neuropsychiatr Dis. 2000;26:111\u20132.","journal-title":"Chin J Neuropsychiatr Dis"},{"key":"2266_CR55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.yic.0000188216.92408.69","volume":"21","author":"A Kreinin","year":"2006","unstructured":"Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006;21:99\u2013103.","journal-title":"Int Clin Psychopharmacol"},{"key":"2266_CR56","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/00004714-200112000-00012","volume":"21","author":"YM Bai","year":"2001","unstructured":"Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol. 2001;21:608\u201311.","journal-title":"J Clin Psychopharmacol"},{"key":"2266_CR57","first-page":"95","volume":"12","author":"Z Zhao","year":"2000","unstructured":"Zhao Z, Chen H, Xie B, Sun S, Wu H, Ma Q, et al. A controlled trial on the use of Zhiyan capsule in clozapine-induced sialorrhoea. Chin J Civ Aff Med. 2000;12:95\u20136.","journal-title":"Chin J Civ Aff Med"},{"key":"2266_CR58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2010.02.1060","volume":"119","author":"CS Liang","year":"2010","unstructured":"Liang CS, Ho PS, Shen LJ, Lee WK, Yang FW, Chiang KT. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res. 2010;119:138\u201344.","journal-title":"Schizophr Res"},{"key":"2266_CR59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jocn.2018.02.011","volume":"51","author":"K Sridharan","year":"2018","unstructured":"Sridharan K, Sivaramakrishnan G. Pharmacological interventions for treating sialorrhea associated with neurological disorders: a mixed treatment network meta-analysis of randomized controlled trials. J Clin Neurosci. 2018;51:12\u20137.","journal-title":"J Clin Neurosci"},{"key":"2266_CR60","first-page":"14","volume":"24","author":"GB Proctor","year":"2014","unstructured":"Proctor GB, Carpenter GH. Salivary secretion: mechanism and neural regulation. Saliva: Secret Funct. 2014;24:14\u201329.","journal-title":"Saliva: Secret Funct"},{"key":"2266_CR61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/prd.12116","volume":"70","author":"GB Proctor","year":"2016","unstructured":"Proctor GB. The physiology of salivary secretion. Periodontology 2000. 2016;70:11\u201325.","journal-title":"Periodontology 2000"},{"key":"2266_CR62","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0922-4106(94)90047-7","volume":"269","author":"SH Zorn","year":"1994","unstructured":"Zorn SH, Jones SB, Ward KM, Liston DR. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol: Mol Pharmacol. 1994;269:R1\u20132.","journal-title":"Eur J Pharmacol: Mol Pharmacol"},{"key":"2266_CR63","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.archoralbio.2007.07.012","volume":"53","author":"AT Ryberg","year":"2008","unstructured":"Ryberg AT, Warfvinge G, Axelsson L, Soukup O, G\u00f6trick B, Tobin G. Expression of muscarinic receptor subtypes in salivary glands of rats, sheep and man. Arch Oral Biol. 2008;53:66\u201374.","journal-title":"Arch Oral Biol"},{"key":"2266_CR64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0722.2011.00832.x","volume":"119","author":"T Godoy","year":"2011","unstructured":"Godoy T, Riva A, Ekstr\u00f6m J. Clozapine\u2010induced salivation: interaction with N\u2010desmethylclozapine and amisulpride in an experimental rat model. Eur J oral Sci. 2011;119:275\u201381.","journal-title":"Eur J oral Sci"},{"key":"2266_CR65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0893-133X(98)00048-7","volume":"20","author":"MC Olianas","year":"1999","unstructured":"Olianas MC, Maullu C, Onali P. Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology. 1999;20:263\u201370.","journal-title":"Neuropsychopharmacology"},{"key":"2266_CR66","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","volume":"100","author":"C Sur","year":"2003","unstructured":"Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc Natl Acad Sci. 2003;100:13674\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"2266_CR67","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0022034509356055","volume":"89","author":"J Ekstr\u00f6m","year":"2010","unstructured":"Ekstr\u00f6m J, Godoy T, Riva A. Clozapine: agonistic and antagonistic salivary secretory actions. J Dent Res. 2010;89:276\u201380.","journal-title":"J Dent Res"},{"key":"2266_CR68","first-page":"77","volume":"10","author":"G Lamba","year":"2011","unstructured":"Lamba G, Ellison JM. Reducing clozapine-induced hypersalivation. Curr Psychiatry. 2011;10:77\u20139.","journal-title":"Curr Psychiatry"},{"key":"2266_CR69","doi-asserted-by":"crossref","first-page":"102712","DOI":"10.1016\/j.autneu.2020.102712","volume":"228","author":"T Sato","year":"2020","unstructured":"Sato T, Yajima T, Fujita M, Kobashi M, Ichikawa H, Yoshida R, et al. Orexin A and B in the rat superior salivatory nucleus. Autonomic Neurosci. 2020;228:102712.","journal-title":"Autonomic Neurosci"},{"key":"2266_CR70","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1111\/ejn.12967","volume":"42","author":"V Linehan","year":"2015","unstructured":"Linehan V, Trask RB, Briggs C, Rowe TM, Hirasawa M. Concentration-dependent activation of dopamine receptors differentially modulates GABA release onto orexin neurons. Eur J Neurosci. 2015;42:1976\u201383.","journal-title":"Eur J Neurosci"},{"key":"2266_CR71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00427261","volume":"81","author":"A Mizuchi","year":"1983","unstructured":"Mizuchi A, Kitagawa N, Miyachi Y. Regional distribution of sultopride and sulpiride in rat brain measured by radioimmunoassay. Psychopharmacol (Berl). 1983;81:195\u20138.","journal-title":"Psychopharmacol (Berl)"},{"key":"2266_CR72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","volume":"205","author":"AI Abbas","year":"2009","unstructured":"Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacol (Berl). 2009;205:119\u201328.","journal-title":"Psychopharmacol (Berl)"},{"key":"2266_CR73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/sj.bjp.0703303","volume":"130","author":"DM Bourdon","year":"2000","unstructured":"Bourdon DM, Camden JM, Landon LA, Levy FO, Turner JT. Identification of the adenylyl cyclase-activating 5-hydroxytryptamine receptor subtypes expressed in the rat submandibular gland. Br J Pharm. 2000;130:104\u20138.","journal-title":"Br J Pharm"},{"key":"2266_CR74","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/0006-2952(93)90211-E","volume":"45","author":"T Stanton","year":"1993","unstructured":"Stanton T, Bolden-Watson C, Cusack B, Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol. 1993;45:2352\u20134.","journal-title":"Biochem Pharmacol"},{"key":"2266_CR75","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jclinepi.2004.02.018","volume":"57","author":"TA Trikalinos","year":"2004","unstructured":"Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol. 2004;57:1124\u201330.","journal-title":"J Clin Epidemiol"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02266-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02266-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02266-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T21:45:16Z","timestamp":1703022316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02266-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2266"],"URL":"https:\/\/doi.org\/10.1038\/s41380-023-02266-x","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"1 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CUC reported receiving personal fees from Alkermes plc, Allergan plc, Angelini Pharma, Gedeon Richter, Gerson Lehrman Group, Intra-Cellular Therapies, Inc, Janssen Pharmaceutica\/Johnson&Johnson, LB Pharma International BV,H Lundbeck A\/S, MedAvante-ProPhase, Medscape, Neurocrine Biosciences, Noven Pharmaceuticals, Inc, Otsuka Pharmaceutical Co, Inc, Pfizer, Inc, Recordati, Rovi, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Inc, Supernus Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals, Acadia Pharmaceuticals, Inc, Axsome Therapeutics, Inc, Indivior, Merck&Co, Mylan NV, MedInCell, and Karuna Therapeutics and grants from Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Berlin Institute of Health, the National Institute of Mental Health, Patient Centered Outcomes Research Institute, and the Thrasher Foundation outside the submitted work; receiving royalties from UpToDate; and holding stock options in LB Pharma. No other disclosures were reported. AdB has received research support from Janssen, Lundbeck, and Otsuka and lecture fees for educational meeting from Chiesi, Lundbeck, Roche, Sunovion, Viatris, Recordati, Angelini and Takeda; he has served on advisory boards for Eli Lilly, Jansen, Lundbeck, Otsuka, Roche, and Takeda, Chiesi, Recordati, Angelini, Vitria. MS has received honoraria\/has been a consultant for Angelini, Lundbeck, and Otsuka. MF received honoraria from the American Society of Clinical Psychopharmacology (ASCP), Angelini, Lundbeck, Bristol Meyer Squibb, and Boehringer-Ingelheim for his speaker activities. GP has received research grants and\/or has been a consultant for, and\/or has been a speaker for: Angelini, Lundbeck, Janssen, Otsuka, Pfizer, Roche, Eisai. DS is funded in part by an NHMRC EL2 Fellowship GNT1194635. FS has received honoraria\/has been a consultant for Janssen (past five years). The other authors report no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}